Kynurenine Metabolism in Multiple Sclerosis: A Metabolic Link to Neuroprotection
Multiple sclerosis (MS) is a neurological disorder whose underlying pathogenesis involves complex interactions between inflammatory, immunological, and neurodegenerative processes. In the study “Kynurenine Metabolism in Multiple Sclerosis,” Hartai and colleagues investigated whether alterations in tryptophan metabolism might contribute to these processes. Of particular interest is the kynurenine pathway, which generates several biologically active metabolites, including quinolinic acid (QUIN) and kynurenic acid (KYNA). These compounds exert opposing effects on excitatory neurotransmission: QUIN acts as an excitatory receptor agonist, whereas KYNA has inhibitory and potentially neuroprotective properties. KYNA is produced from L-kynurenine through the activity of two enzymes, kynurenine aminotransferase I (KAT I) and kynurenine aminotransferase II (KAT II). Importantly, KYNA is described as an endogenous antagonist of ionotropic excitatory amino-acid receptors, suggesting that changes in its production could influence neuronal vulnerability to excessive excitatory stimulation.
Excitotoxicity as a Possible Mechanism in Multiple Sclerosis
The study is grounded in the hypothesis that excitotoxicity may contribute to the pathological mechanisms of MS. Excessive activation of glutamate receptors can damage nervous tissue, and oligodendrocytes—the cells responsible for producing myelin—express AMPA/kainate-type glutamate receptors. This observation provides a plausible mechanism through which excessive excitatory signaling could contribute to demyelination and axonal injury. Experimental evidence cited by the authors further strengthens this hypothesis: blockade of AMPA receptors was reported to improve neurological signs in experimental autoimmune encephalomyelitis, an animal model of MS, while increasing oligodendrocyte survival and reducing axonal damage. At the same time, previous studies had reported decreased KYNA concentrations in the cerebrospinal fluid of patients with MS. Because KYNA can counteract excitatory signaling, such a decrease may represent a reduction in an endogenous neuroprotective mechanism and therefore provide additional evidence that the kynurenine pathway participates in MS-associated neurotoxicity.
Investigating Kynurenine Metabolism in Peripheral Blood
Hartai and colleagues sought to determine whether changes in the kynurenine system could also be detected outside the central nervous system. Their study examined 13 patients with the intermittent form of MS during acute exacerbation and compared them with 14 age-matched healthy volunteers. The patients had experienced more than two relapses, and blood samples were collected within one to three days after the appearance of new neurological symptoms. None of the participants were taking medication or had received steroid therapy during the preceding six months, reducing the likelihood that the measured metabolic differences were caused by recent treatment. The investigators focused on three objectives: detecting KAT I and KAT II in red blood cells (RBCs) and plasma, measuring the activities of these enzymes, and determining KYNA concentrations in the same compartments. This design allowed the researchers to assess whether peripheral kynurenine metabolism changes during an MS exacerbation and whether those changes might reflect systemic responses to disease activity.
Experimental Measurement of Enzyme Activity and Kynurenic Acid
The biochemical methodology combined enzyme activity assays with high-performance liquid chromatography. KAT I and KAT II activities were measured in RBC and plasma samples under different pH conditions selected for the respective enzymes. The reaction mixtures contained L-kynurenine as the substrate together with 2-oxoglutarate and pyridoxal-5′-phosphate, and enzyme activity was determined spectrophotometrically. Results from RBCs were normalized to hemoglobin content, whereas plasma measurements were normalized to total protein concentration. KYNA concentrations were measured by high-performance liquid chromatography with fluorescence detection after protein precipitation, purification using cation-exchange resin, and chromatographic separation. Statistical comparisons were conducted using one-way analysis of variance followed by Fisher’s test, with a P-value below 0.05 considered statistically significant. Through this analytical approach, the researchers were able to compare both the enzymatic capacity to produce KYNA and the actual concentration of this neuroactive metabolite between patients with MS and healthy controls.
Increased KAT Activity and Plasma KYNA in Multiple Sclerosis
The results revealed notable differences between patients with MS and control participants. Both KAT I and KAT II were detectable in RBCs and plasma, but their activities differed according to biological compartment. In RBCs, KAT I activity increased from approximately 243 pmol/mg Hb/h in controls to approximately 412 pmol/mg Hb/h in MS patients, while KAT II activity increased from approximately 347 to 475 pmol/mg Hb/h. Both differences were statistically significant. By contrast, neither KAT I nor KAT II activity changed significantly in plasma. KYNA concentrations displayed a related pattern: plasma KYNA increased significantly from approximately 45 nM in controls to 77 nM in patients with MS. RBC KYNA concentrations were also higher in the MS group, rising from approximately 38 to 63 nM, although this difference did not reach statistical significance. Collectively, these findings demonstrate that acute MS exacerbation is associated with measurable alterations in peripheral kynurenine metabolism, particularly within red blood cells and circulating plasma.
A Compensatory Neuroprotective Response?
The authors interpreted the elevated KAT activity and increased plasma KYNA concentration as a possible compensatory protective response to excitotoxic processes. Because KAT enzymes regulate the formation of KYNA, enhanced activity could increase the capacity of peripheral tissues to generate this inhibitory metabolite. Interestingly, earlier research had demonstrated decreased KYNA in the cerebrospinal fluid of patients with MS, creating an apparent contrast between central and peripheral compartments. Hartai and colleagues proposed that reduced cerebrospinal KYNA might reflect increased consumption during excitotoxic stress, whereas elevated peripheral production might represent an attempted protective response. They further suggested that KYNA could be transported out of RBCs, potentially explaining why increased KAT activity was not accompanied by a statistically significant increase in RBC KYNA. However, the protective capacity of this peripheral response may be limited because KYNA does not readily cross the blood–brain barrier. Thus, increased peripheral KYNA production may signal systemic metabolic adaptation without necessarily providing sufficient protection inside the central nervous system.
Scientific Significance and Therapeutic Implications
The study provides evidence that the kynurenine pathway is altered during exacerbations of multiple sclerosis and may therefore participate in the disease process. The simultaneous increase in RBC KAT activity and plasma KYNA suggests that MS is associated not only with changes in the central nervous system but also with detectable metabolic responses in peripheral blood. The authors proposed that these alterations might arise from excitotoxic molecules released from the central nervous system or from systemic immunological stimulation, although the responsible compounds were not identified. They specifically noted QUIN as one possible candidate while emphasizing that this remained speculative. The study also has an important limitation: only 13 patients with MS were examined, meaning that the conclusions must be interpreted cautiously. Nevertheless, the findings raise the possibility that manipulating kynurenine metabolism could represent a therapeutic strategy. The authors therefore identified KYNA analogues and drugs capable of modifying KAT activity as potential directions for future investigation, positioning the kynurenine system as a biologically intriguing link between excitotoxicity, metabolic compensation, and neuroprotection in MS.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Hartai, Z., Klivényi, P., Janaky, T., Penke, B., Dux, L., & Vécsei, L. (2005). Kynurenine metabolism in multiple sclerosis. Acta Neurologica Scandinavica, 112(2), 93-96.
